Establishment of the endocrine variant extractor and its clinical application in identifying a novel GATA3 mutation in HDR syndrome
By
Yunseo Han
Danbi Song
Minsoo Noh
Mikyung Kang
Young Sil Eom
Hunsang Lee
Sihoon Lee
July 1, 2026
Clinical Scorecard: Development of the Endocrine Variant Extractor and Its Role in Detecting a Novel GATA3 Mutation Associated with HDR Syndrome
At a Glance
Category Detail
Condition HDR Syndrome Key Mechanisms GATA3 mutations leading to endocrine dysfunction Target Population Patients with hypoparathyroidism, deafness, and renal dysplasia Care Setting Clinical genetic diagnostics
Key Highlights
EVE filters >300,000 raw variants to actionable candidates. Identified a novel GATA3 frameshift variant in a HDR syndrome patient. Automated analysis reduces manual data review by >99.6%. EVE integrates pathogenicity scores and clinical databases for variant assessment. Framework aims to create a comprehensive endocrine variant atlas. Guideline-Based Recommendations
Diagnosis
Utilize EVE for genetic screening in endocrine disorders. Management
Implement personalized treatment based on identified genetic variants. Monitoring & Follow-up
Regularly assess patients for clinical manifestations of HDR syndrome. Risks
Consider the variability in symptom expression among HDR syndrome patients. Patient & Prescribing Data
Individuals with suspected genetic endocrine disorders.
Genetic confirmation aids in targeted management strategies.
Clinical Best Practices
Adopt standardized bioinformatics workflows for genomic analysis. Encourage genetic counseling for patients with rare endocrine disorders. Related Resources & Content
